Tso, F, Y; Lidenge, S, L; Mwaiselage, J; West, J, T; Wood, C; Poppe, L, K.; Peña, P, B.; Privatt, S, R.; Bennett, S, J.; Ngowi, J, R.; Belshan, M; Siedlik, J, A.; Raine, M, A.; Ochoa, J, B.; Garcia-Diaz8, J; Nossaman, B; Buckner, L; Roberts, W. M; Dean, M, J.; Ochoa, A, C.
(PLoS ONE, 2021)
Background Neutralizing-antibody (nAb) is the major focus of most ongoing COVID-19 vaccine trials. However, nAb response against SARS-CoV-2, when present, decays rapidly. Given the myriad roles of antibodies in immune ...